文献速递骨质疏松与钙磷/甲状旁腺

骨化三醇单药治疗儿童与成人X连锁低磷血症的前瞻性开放标签研究

Treatment of Children and Adults With X-Linked Hypophosphatemia With Calcitriol Alone: A Prospective, Open-Label Study.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该研究为1年前瞻性单臂开放标签研究,纳入美国4岁及以上XLH患者,比较骨化三醇单药治疗基线与12个月结局。结论认为骨化三醇单药安全耐受,对矿物质代谢和佝偻病有适度获益。

要点

  • 骨化三醇单药治疗XLH安全耐受,但血磷无改善。
  • 儿童佝偻病部分改善,身高z评分无变化。
  • 成人桡骨骨皮质厚度增加,肾钙质沉着稳定。

核心结论

  • 骨化三醇单药治疗XLH安全且耐受良好,对矿物质代谢实验室指标和佝偻病有适度获益。

研究设计与样本

  • 1年前瞻性单臂开放标签研究,比较基线与12个月结局,参与者来自美国内分泌门诊,年龄≥4岁,基线25羟维生素D≥20 ng/mL且血钙正常。

主要发现

  • 12个月优化骨化三醇治疗后血磷无变化。
  • 4例开放骨骺儿童中2例佝偻病改善,身高z评分无变化。
  • 肾钙质沉着评分保持稳定。

关键数值与推荐

  • 4例参与者出现轻度高钙血症,2例出现高钙尿症,经骨化三醇剂量调整后缓解。

临床怎么用

  • 骨化三醇单药可作为XLH的一种安全治疗选择,但需监测血钙、尿钙及肾钙质沉着。

局限性

  • 单臂开放标签设计,样本量小,缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Preclinical studies demonstrate that treatment with calcitriol attenuates skeletal complications in mice with X-linked hypophosphatemia (XLH). OBJECTIVE: This work aimed to assess serum markers of mineral metabolism, nephrocalcinosis, skeletal microarchitecture, growth, and evidence of rickets following calcitriol monotherapy in children and adults with XLH. METHODS: A 1-year, prospective, single-arm, open-label study was conducted comparing baseline and 12-month outcomes. Participants were recruited from outpatient endocrinology clinics in the United States. Data were collected in a research unit. Eligible participants were aged 4 years or older, not pregnant, with baseline 25-hydroxyvitamin D of 20 ng/mL or greater and normal serum calcium. Participants were treated with calcitriol, with dose based on serum and urinary calcium concentrations, for 1 year. The primary end points were change in serum phosphate and nephrocalcinosis (all participants) and rickets severity score (children). Secondary end points included changes in additional markers of mineral metabolism, skeletal microarchitecture parameters via high-resolution peripheral quantitative computed tomography (all participants), and height z-scores (children). RESULTS: Serum phosphate did not change over 12 months of optimized calcitriol treatment. Rickets improved in 2 of 4 children with open epiphyses; height z-scores were unchanged. Nephrocalcinosis scores remained stable. Adults had increased cortical thickness at the radius diaphysis (P = .012). Serum alkaline phosphatase decreased in children (P = .021) and parathyroid hormone trended lower both in children (P = .065) and adults (P = .063). Four participants developed mild hypercalcemia and 2 developed hypercalciuria that resolved with calcitriol titration. CONCLUSION: Calcitriol monotherapy is safe and well-tolerated in XLH, with modest benefits on laboratory indices of mineral metabolism and rickets.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Mitchell D, Jordan M, Gehman S, et al. Treatment of Children and Adults With X-Linked Hypophosphatemia With Calcitriol Alone: A Prospective, Open-Label Study. J Clin Endocrinol Metab. 2026. PMID: 41137448. doi:10.1210/clinem/dgaf585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。